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Like diamonds, most viruses are forever. The ability to adapt by 
mutation of their genomes may change a virus and its behaviour over 
time, but ‘once a virus, always a virus’.
Viruses have been evolving with life on this planet for several billion 
years. Most infect the dominant cellular organisms – prokaryotes 
such as bacteria and archaea – and only a very small subset infect 
mammalian hosts. Many of these are ‘orphan’ viruses, causing transient 
or asymptomatic infections that are of little concern. However, a few 
that are highly infectious and virulent may have serious health and/or 
economic impacts, and are of considerable concern. The global human 
population is currently focused on one particular coronavirus, SARS-
CoV-2, which emerged unexpectedly to become highly infectious to 
humans, and which has swept the planet.
Viruses may become more or less infectious over time, and 
symptoms from the diseases they cause may become milder or more 
severe. As new viruses enter the human population immunity levels 
will increase, and antiviral prophylaxis, including vaccines, is likely 
to become the norm, but most viruses still live on. There has been 
some, but limited, success in eradicating disease-causing viruses: 
smallpox was widespread in Europe a thousand years ago,[1] but was 
declared to have been eradicated by the World Health Organization 
in 1980. As a result of a concerted vaccine campaign over decades, 
wild-type poliovirus type 1 – one of the three that were common – is 
now only present in two south-east Asian countries, while poliovirus 
types 2 and 3 have been eradicated in their ‘wild’ forms. The deadly 
rinderpest virus, once a scourge of cattle and wildlife, was also 
eradicated, in 2011, as a result of sustained vaccination campaigns. 
Conversely, other viruses, such as the rhinoviruses, coronaviruses 
and adenoviruses that cause the common cold, as well as influenza 
viruses, are permanent residents in the global human population, 
re-emerging annually as seasonal epidemics.
Not all viruses infecting humans or animals are harmful, and some 
have evolved with their hosts over millions of years: many human 
papillomaviruses, for example, seem to be harmless commensals 
of the skin, even though they have distant relatives that can cause 
serious diseases such as cervical, anal, and head and neck cancers. 
Evidence of past retroviral infections can be found as integrated DNA 
sequences in all animal genomes: up to 10% of the human genome 
is composed of degraded retrovirus genomes, and the evolution of 
many animal lineages can be tracked according to which integrated 
retroviral genomes they share. Indeed, ancient retroviruses have 
shaped the evolution of many mammalian and human cellular and 
developmental pathways.[2,3]
On the other hand, most of the viruses that do pose threats 
to the health of humans and their livestock have emerged in 
relatively recent times and result almost exclusively from zoonotic 
transmission: HIV-1 and HIV-2 crossed into humans in West 
Africa from chimpanzees and sooty mangabeys, respectively, as 
long ago as the early 1900s. Both the deadly Ebola and the related 
Marburg viruses were unknown prior to the late 1960s, and emerged 
as a result of human encroachment into wilderness areas. The 
mosquito-transmitted yellow fever and dengue and West Nile and 
Zika viruses have spread from Africa around the world as a result 
of human activity. Coronaviruses have been increasingly important 
more recently, with emergence into the human population of severe 
acute respiratory syndrome virus (SARS-CoV) in 2002, Middle East 
respiratory syndrome virus (MERS-CoV) in 2012, and what is now 
known as SARS-CoV-2 in 2019. While the first two viruses were 
fortunately limited in their spread, given that their case fatality rates 
were nearly 10% and over 30%, respectively, it is worth noting that 
the four coronaviruses that cause the common cold also emerged in 
humans over a period of several hundred years, and may originally 
have caused much more severe disease.
SARS-CoV-2 is therefore just the most recent coronavirus to 
emerge from obscure origins to cause widespread human disease. 
However, the core issue is not whether SARS-CoV-2 is here to stay, like 
This open-access article is distributed under 
Creative Commons licence CC-BY-NC 4.0.
ISSUES IN PUBLIC HEALTH
Viruses, variants and vaccines
D A Cowan,1 BSc, MSc, PhD; S G Burton,2 BSc, BSc Hons, MSc, PhD; E P Rybicki,3,4 BSc Hons, MSc, PhD;  
A-L Williamson,4 BSc, BSc Hons, PhD; R A Dorrington,5 BSc Agric, BSc Hons, MSc, PhD; M S Pepper,6 MB ChB, PhD, MD, PD
1  Centre for Microbial Ecology and Genomics, Department of Biochemistry, Genetics and Microbiology, Faculty of Natural and Agricultural 
Sciences, University of Pretoria, South Africa 
2  Future Africa and Department of Biochemistry, Genetics and Microbiology, Faculty of Natural and Agricultural Sciences, University of Pretoria, 
South Africa 
3 Biopharming Research Unit, Department of Molecular and Cell Biology, Faculty of Health Sciences, University of Cape Town, South Africa
4 Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences, University of Cape Town, South Africa
5 Department of Biochemistry and Microbiology, Faculty of Science, Rhodes University, Makhanda, South Africa 
6  Institute for Cellular and Molecular Medicine, Department of Immunology, and South African Medical Research Council Extramural Unit for 
Stem Cell Research and Therapy, Faculty of Health Sciences, University of Pretoria, South Africa
Corresponding author: D A Cowan (don.cowan@up.ac.za)
The current SARS-CoV-2 pandemic has brought a number of major global clinical, sociological and economic issues into sharp focus. 
We address some of these issues, focusing on short-term factors such as virus mutations and vaccine efficacy, and also considering the 
longer-term implications of the current pandemic. We discuss societal responses to the presence of a pathogen that will probably remain in 
circulation for decades or longer, and to future new emergent viruses.
S Afr Med J. Published online 1 March 2021. https://doi.org/10.7196/SAMJ.2021.v111i5.15578
2       Published online ahead of print
IN PRACTICE
its common cold-causing relatives, but how we as the human race will 
deal with it in the medium to long term. How will human behaviour 
and lifestyles ‘normalise’ in a ‘post-COVID pandemic’ world?
At the time of writing, the approval and distribution of a small (but 
rapidly increasing) number of effective anti-COVID-19 vaccines has 
offered hope to the global human population[4] that, through 2021, 
the current pandemic will be contained. It is highly likely, however, 
given the evidence of previous coronavirus ‘domestication’, that 
COVID-19 will not disappear (i.e. will not be fully eradicated).
Life after vaccines
As vaccines are becoming available at a hitherto unprecedented rate, 
the medical responses to COVID-19 are transitioning from non-
pharmaceutical interventions such as hygiene, social distancing and 
lockdowns to national and international vaccination programmes. 
There is no doubt that immunisation of the majority of the global 
community is a key requirement for controlling COVID-19. 
However, the limitations of vaccine production capacity globally, 
and in particular the issue of affordability by low- to middle-
income countries (LMICs), are constraining the pace of vaccination 
programmes. The constraints on vaccine production and access 
bring with them a host of social and political issues, and equity is 
one of these.[5] High-income countries’ governments have ‘bought 
up’ large proportions of the available vaccines, so-called vaccine 
nationalism, leaving the LMICs, which account for the majority of the 
global population, in the disadvantaged position of not being able to 
vaccinate their vulnerable (and often poverty-stricken) communities, 
even where financial provision has been made.
It is possible that in the short term, requirements for SARS-CoV-2 
vaccination certification will become a norm for international 
travel, as they already are for travel to several countries for yellow 
fever virus: this has the potential to exacerbate the divide between 
countries able to provide vaccinations and those not yet in a position 
to do so. In turn, it will impact on many national travel and tourism 
industries. It could also result in a thriving black market in fake 
certificates, as already occurs with yellow fever and for PCR results 
for SARS-CoV-2.
Until vaccination programmes have been extensively implemented 
and enough people have acquired immunity to SARS-CoV-2, 
governments and communities will need to continue to rely on 
non-pharmaceutical interventions to contain the spread of the 
virus. These regulations bring another set of concerns, including a 
heavy impact on national and regional economies and an increase in 
socioeconomic hardship.
In some cases, restrictions are being imposed without clarity of 
purpose, with misguided intentions and even with the intention 
of effecting political or personal agenda-driven goals. In many 
poverty-ridden communities, compliance with lockdown restrictions 
is almost impossible, for various social and economic reasons. The 
consequence is that infections are surging, and at the same time 
unemployment is increasing, with the wave of viral infection being 
closely followed by secondary effects, including a substantial rise in 
mental ill health.
The essential consideration in respect of these social and economic 
impacts is that it is likely to be some years before the global 
community has developed sufficient immunity to overcome the 
COVID-19 pandemic, and national and international agendas will 
need to take this into account.
New viral variants
RNA viruses naturally mutate faster than DNA viruses and host 
DNA. The incidence of mutation may increase as environmental 
pressures increase. A lineage containing a limited number of new 
mutations is generally referred to as a new variant (not a new strain). 
Mutations are often functionally neutral (do not affect the viral 
phenotype), but are occasionally functionally important. Over the 
period around Christmas 2020, scientists identified two new SARS-
CoV-2 variants, one in the UK (B.1.1.7)[6] and one in South Africa 
(SA) (B.1.351).[7] Both had acquired a number of point mutations 
(nucleotide changes leading to amino acid changes or deletions), a 
few of which have occurred in the viral spike (S) protein that binds to 
the host ACE2 receptor protein to initiate host cell infection. These 
mutations have resulted in a significant increase in viral infectivity, 
meaning that these new variants tend to spread more rapidly within 
the host (human) population. These new variants are responsible 
for the very rapid second-wave infection rates that have now been 
recorded in many countries, including the UK and SA.
Widespread concern has been expressed that some of the currently 
available vaccines being distributed across the globe may be less 
effective against the B.1.351 variant, since the viral spike protein 
contains the antigens chosen for vaccine development. However, 
expert opinion has been mostly reassuring: ‘both vaccines and 
natural infections lead to a broad immune response that targets many 
parts of the virus’,[7] and changes in a limited number of viral protein 
structures are unlikely to affect the efficacy of current (and future) 
vaccines, unless significantly more of these changes are concentrated 
in the S protein. We now know that at least one vaccine does have 
reduced efficacy against the SA variant virus (at least, in young people 
with mild infections), while a second appears to retain its efficacy in 
all age groups.
Many SARS-CoV-2 variants now exist across the world, and there 
are probably many more that have not yet been detected because of 
absent or inefficient surveillance programmes. Additional SARS-
CoV-2 variants will continue to emerge in the future – we can be sure 
of this as long as the pandemic continues – although maybe at a slower 
rate as immunity (natural and acquired) becomes the norm in the 
global human population. Moreover, transmission to farmed animals 
such as mink could select for a different spectrum of variants to those 
that occur in humans – and these may readily be transmitted back to 
humans, as happened with the H1N1 2009pdm influenza virus. Some 
variants will show changes in functional properties, like the UK VOC 
202012/01 and SA B.1.351 variants, that may be significantly more 
transmissible than wild-type viruses, and some of these changes may 
additionally influence the virulence of the virus (although this does 
not generally appear to have been the case to date).
There is little we can do to prepare ourselves for these possibilities, 
other than to ensure that we continue to maintain a robust level of 
surveillance, in particular whole-genome virus sequence surveillance. 
We can have some confidence, however, that the current anti-
COVID-19 vaccines, and the many more to follow, will very probably 
retain their efficacy, given the much lower rate of mutation for 
SARS-CoV-2 relative to influenza viruses and the lack of evidence 
for immune escape in existing variants. It is also a fact that the new 
vaccine technologies being applied to the COVID-19 problem – the 
various adenovirus vectors (e.g. Astra-Zeneca, Johnson & Johnson, 
Gamaleya Center, CanSino Biologics), mRNA (Moderna, Pfizer-
BioNtech) and subunit vaccines (Novavax, Medicago) – make it 
relatively quick and easy to adapt the vaccines to accommodate 
new mutations in emerging variants, thereby ensuring that vaccines 
remain highly effective. There is a very real possibility that annual 
booster vaccines will become the routine in years to come, as happens 
for seasonal influenza. Reassuringly, Pfizer-BioNtech announced that 
the efficacy of their vaccine is not affected by the mutations in the UK 
and SA variants,[8] and new data released by the US Food and Drug 
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Administration on the Johnson & Johnson product show that the 
vaccine is also highly effective against both variants.
The post-COVID-19 world
How will the world adjust, once the COVID-19 pandemic has 
subsided? In addition to investing in continuous rapid development 
and testing of vaccines, we will need to ensure that everyone is 
equipped to manage ‘normal’ (working) life in an increasingly 
infectious environment.
One key to managing future virus epidemics is through broad, 
meaningful community-based education, driven by heightened 
awareness that compliance will come from everyone being provided 
with relevant information, which must be available, understandable 
and accurate. While medical scientists will continue their endeavours 
to understand viral diseases and find therapies, people from all 
disciplines will need to work in integrated, collaborative ways to 
provide information and educate communities. Moreover, leadership 
in science communication will be as important as leadership in 
science itself.
The next viral pandemic
COVID-19 is just the latest in a series of severe viral diseases 
circulating in the human population. In addition, an ever-increasing 
number of coronaviruses are being discovered in mammalian hosts 
(particularly bats and primates), which may have the potential 
to drive the next viral pandemic. While some have argued that a 
critical priority is therefore to invest in increased pan-viral genomic 
surveillance to facilitate the early identification of potential new viral 
pathogens, the reality is that this is a shotgun approach that will be 
exorbitantly expensive, and can only identify potential pathogens. A 
more directed approach that surveys diseased animals and humans 
is far more likely to yield important information at a far lower cost: 
a current example is the seroepidemiological and genomic surveys 
of stock animals in SA for viruses associated with encephalitic 
disease. In addition, there needs to be a substantial investment in the 
development of a stock of antiviral compounds including pan-family 
drugs that have already progressed through preclinical trials, and that 
can rapidly be deployed against emerging viral pathogens, in parallel 
with the development of effective vaccines.
African vaccine production capacity
It is perhaps not widely known that SA currently manufactures just 
one component of one paediatric combination vaccine: the country 
effectively has no significant human vaccine manufacturing capacity. 
We were therefore unable to respond to the 2009 H1N1 influenza 
virus pandemic, and in fact had to wait until 2011 for deployment 
of vaccines to the general population. While the government of 
the time made declarations of intent about establishing influenza 
virus manufacturing capacity, nothing was done in this regard. The 
same is true for the whole of Africa: while Nigeria, Tunisia, Senegal 
and Egypt do manufacture human vaccines, capacity and variety 
are severely limited, with only BCG, yellow fever, cholera and DTP 
vaccines currently being commercially available, and usually only for 
domestic use.[9] There is therefore effectively no emergency-response 
vaccine manufacturing capacity in a continent that is home to over 
1 billion people: this is in stark contrast to China, India, Russia and 
Brazil, all of which have significant capacity, and all of which are 
involved in the global COVID-19 vaccine response. This MUST 
change, or Africa will always be at the end of the global queue for 
emerging disease vaccines – and the next pandemic could well be far 
worse than the present one.
Conclusions
What is important at this stage, and looking ahead, is that we 
prepare ourselves for a future where mutant variants of known 
viruses, and indeed entirely new viruses, will emerge; further 
pandemics will sweep across the world, and we will need better 
ways to respond. A more severe disease agent than the present one 
would test most of the world – and Africa potentially more than 
anywhere else. Viruses are with us forever! However, the diseases 
they cause need not be.
Recommendations
• Establish and expand existing surveillance of pathogens causing 
severe diseases in humans and animals to identify novel and 
emerging pathogens: this should be linked to pathogenomic 
surveillance programmes where these already exist and the 
establishment of new programmes where they do not.
• Increase drug repurposing and discovery platforms and 
programmes aimed at existing pathogens, in anticipation of novel 
future pathogens.
• Expand pharmaceutical production capacity to provide localised 
supply pipelines of affordable therapeutics and vaccines, together 
with associated primary healthcare infrastructure to support mass 
vaccination initiatives.
• Promote equity in terms of access to medications and vaccines 
and implement strategies that mitigate against hoarding by higher-
income countries to the detriment of LMICs.
• Finally, and very importantly, increase educational and awareness 
programmes and provide scientifically sound and accessible 
information to the general public, in part to mitigate the infodemic 
that erodes public trust in vaccine and other preventive (non-
pharmaceutical) programmes.
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